GMP IPO Watch
DSP Nifty Healthcare ETF
DSP Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | -1.49% | +0.07% | 213 of 235 |
| 1M | -4.40% | -4.22% | 110 of 235 |
| 3M | -2.69% | -3.75% | 80 of 233 |
| 6M | +12.02% | -0.40% | 14 of 224 |
| YTD | +8.85% | -5.36% | 11 of 235 |
| 1Y | +8.94% | -1.03% | 19 of 194 |
| 2Y | +3.25% | +1.20% | 52 of 151 |
| INCEPTION | +13.61% | — | — |
Ranked among: Exchange Traded Funds (ETFs) - Other ETF.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +3.84% | +24.00% | -12.58% | 68% | 27% |
| 6M | +7.04% | +26.71% | -12.24% | 73% | 30% |
| 1Y | +9.41% | +23.82% | -4.60% | 94% | 40% |
| 2Y | +10.70% | +15.32% | +3.24% | 100% | 44% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity99.92%
- Debt0.00%
- Cash0.08%
- Other0.00%
Market Cap Split
- Large Cap47.77%
- Mid Cap48.35%
- Small Cap3.80%
- Others0.08%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 40.58 | — |
| P/B | 5.63 | — |
| Price / Sales | 5.82 | — |
| Price / Cash Flow | 31.03 | — |
| Dividend Yield (%) | 0.59 | — |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 16.99% | -1.08% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 10.43% | +0.09% |
| Apollo Hospitals | Equity | 7.42% | -0.45% |
| Laurus Labs | Pharmaceuticals & Biotechnology | 6.81% | +0.40% |
| Cipla | Pharmaceuticals & Biotechnology | 6.69% | -0.13% |
| Dr Reddys Laboratories | Pharmaceuticals & Biotechnology | 6.64% | +0.59% |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 6.24% | -0.15% |
| Max Healthcare Institute | Equity | 6.11% | -0.56% |
| Lupin | Pharmaceuticals & Biotechnology | 4.36% | -0.21% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 4.08% | -0.01% |
| Fortis Healthcare | Equity | 3.54% | -0.52% |
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 3.11% | -0.10% |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 2.75% | +0.07% |
| Zydus Life Science | Pharmaceuticals & Biotechnology | 2.54% | +0.04% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 2.51% | +0.16% |
View all 22 holdings
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 2.36% | +0.00% |
| Biocon | Pharmaceuticals & Biotechnology | 2.28% | -0.25% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 2.04% | — |
| Krishna Institute of Medical Sciences | Equity | 1.76% | — |
| Abbott | Pharmaceuticals & Biotechnology | 1.26% | +0.09% |
| TREPS / Reverse Repo Investments | Reverse Repo / TREPS | 0.10% | — |
| Net Receivables/Payables | Net Current Assets | -0.02% | — |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 14.67 | 14.95 | Low Volatility |
What is this?
Risk as measured by standard deviation is a statistical measure that quantifies the amount of variation or dispersion in a set of data points relative to its mean (average).
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.61 | 0.80 | Poor Risk Adjusted Returns |
What is this?
Higher the value means that fund has been able to give better returns for the amount of risk taken. It helps investors understand the return of an investment compared to its risk, showing whether the returns are due to intelligent investing or simply taking on excess risk. It is calculated by subtracting the risk-free return, defined as an Indian Government Bond, from the fund's returns, and then dividing by the standard deviation of returns.
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.95 | 1.40 | Poor Risk Adjusted Returns |
What is this?
The Sortino Ratio is a financial metric used to measure the risk-adjusted return of an investment. It's a modification of the Sharpe Ratio but with a key difference; it only considers downside risk (the risk of negative returns), rather than total volatility. This means it focuses on how well an investment performs relative to the volatility that leads to losses, ignoring the volatility that results in gains. The idea is that investors are primarily concerned with minimizing losses, and positive volatility is generally seen as a good thing.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.96 | 0.96 | None |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Tracking Difference
Versus Nifty Healthcare TRI, as of Sep 2026.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
| Tata Silver Exchange Traded Fund | +48.34% | — | — | +49.63% |
| Motilal Oswal Nasdaq Q50 ETF | +42.72% | +33.46% | — | +14.40% |
| ICICI PRUDENTIAL SILVER ETF | +38.75% | +46.15% | — | +29.18% |
| Kotak Silver ETF | +38.66% | +46.06% | — | +34.57% |
|
SBI Silver ETF
Regular Plan · Growth
|
+38.60% | — | — | +46.04% |
| Edelweiss Silver ETF | +38.45% | — | — | +44.78% |
|
Zerodha Silver ETF
Direct Plan
|
+38.43% | — | — | +66.17% |
|
Nippon India Silver ETF
Direct Plan
|
+38.33% | +45.74% | — | +30.23% |
| Motilal Oswal Silver ETF | +38.17% | — | — | +73.62% |
|
HDFC Silver ETF
Growth Option
|
+38.01% | +46.24% | — | +40.53% |
More From DSP Asset Managers Private Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
DSP World Mining Overseas Equity Omni FoF
Direct Plan · Growth
|
+40.95% | +31.63% | +20.24% | +9.09% |
| DSP Silver ETF | +38.72% | +45.98% | — | +37.81% |
|
DSP Silver ETF Fund of Fund
Direct Plan · IDCW
|
+34.86% | — | — | +79.79% |
|
DSP US Specific Equity Omni FoF
Direct Plan · Growth
|
+34.44% | +30.67% | +19.57% | +18.15% |
|
DSP World Gold Mining Overseas Equity Omni FoF
Direct Plan · Growth
|
+31.63% | +58.20% | +29.21% | +9.52% |
|
DSP Global Innovation Overseas Equity Omni FoF
Direct Plan · Growth
|
+23.88% | +30.42% | — | +20.48% |
|
DSP Global Clean Energy Overseas Equity Omni FoF
Direct Plan · Growth
|
+22.84% | +22.11% | +10.33% | +7.00% |
| DSP Gold ETF | +20.98% | +36.07% | — | +28.96% |
|
DSP Gold ETF Fund of Fund
Direct Plan · IDCW
|
+20.81% | — | — | +34.41% |
|
DSP Small Cap Fund
Direct Plan · Growth
|
+16.83% | +16.77% | +16.18% | +21.14% |
About This Scheme
Investment Objective
The Scheme seeks to provide returns that, before expenses, correspond to the total return of the underlying index (Nifty Healthcare TRI), subject to tracking errors. There is no assurance that the investment objective of the Scheme will be achieved.
Stated Asset Allocation
A. Equity and Equity Related Securities of companies constituting Nifty Healthcare Index, the Underlying Index : 95% - 100%. B. Cash and Cash Equivalents : 0% - 5% For detailed asset allocation pattern, please refer to the Scheme Information Document
Exit Load
Nil
Fund Managers
Mr. Anil Ghelani, Mr. Diipesh Shah , Ms. Neha Rathi
Mr. Anil Ghelani - Primary, Mr. Diipesh Shah - Comanage, Ms. Neha Rathi - Comanage
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.